These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 26062020)
41. Molecular basis of acute intermittent porphyria: mutations and polymorphisms in the human hydroxymethylbilane synthase gene. Astrin KH; Desnick RJ Hum Mutat; 1994; 4(4):243-52. PubMed ID: 7866402 [TBL] [Abstract][Full Text] [Related]
42. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria. Serrano-Mendioroz I; Sampedro A; Alegre M; Enríquez de Salamanca R; Berraondo P; Fontanellas A Hum Gene Ther; 2018 Apr; 29(4):480-491. PubMed ID: 28990424 [TBL] [Abstract][Full Text] [Related]
43. Acute intermittent porphyria: mutation analysis and identification of gene carriers in a German kindred by PCR-DGGE analysis. Petrides PE Skin Pharmacol Appl Skin Physiol; 1998; 11(6):374-80. PubMed ID: 10343207 [TBL] [Abstract][Full Text] [Related]
44. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria. Marsden JT; Rees DC J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454 [TBL] [Abstract][Full Text] [Related]
45. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Bonkovsky HL; Healey JF; Lourie AN; Gerron GG Am J Gastroenterol; 1991 Aug; 86(8):1050-6. PubMed ID: 1713408 [TBL] [Abstract][Full Text] [Related]
46. Effects of clonidine in a primed rat model of acute hepatic porphyria. Goerz G; Bolsen K; Böhrer H; Fritsch C; Kalka K; Rominger KL Arzneimittelforschung; 1997 Jun; 47(6):731-3. PubMed ID: 9239451 [TBL] [Abstract][Full Text] [Related]
47. Human hydroxymethylbilane synthase: Molecular dynamics of the pyrrole chain elongation identifies step-specific residues that cause AIP. Bung N; Roy A; Chen B; Das D; Pradhan M; Yasuda M; New MI; Desnick RJ; Bulusu G Proc Natl Acad Sci U S A; 2018 Apr; 115(17):E4071-E4080. PubMed ID: 29632172 [TBL] [Abstract][Full Text] [Related]
48. Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP). Solis C; Lopez-Echaniz I; Sefarty-Graneda D; Astrin KH; Desnick RJ Mol Med; 1999 Oct; 5(10):664-71. PubMed ID: 10602775 [TBL] [Abstract][Full Text] [Related]
49. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Sardh E; Andersson DE; Henrichson A; Harper P Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):66-71. PubMed ID: 19268004 [TBL] [Abstract][Full Text] [Related]
50. Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin. Rosipal R; Puy H; Lamoril J; Martasek P; Nordmann Y; Deybach JC Scand J Clin Lab Invest; 1997 May; 57(3):217-24. PubMed ID: 9238757 [TBL] [Abstract][Full Text] [Related]
51. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels. Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344 [TBL] [Abstract][Full Text] [Related]
52. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921 [TBL] [Abstract][Full Text] [Related]
53. Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP. Chen B; Wang M; Gan L; Zhang B; Desnick RJ; Yasuda M Mol Genet Metab; 2019 Nov; 128(3):382-390. PubMed ID: 30777612 [TBL] [Abstract][Full Text] [Related]